Page 2 - Contract Pharmacies News Today

Last week, we hosted an informative webinar on the 340B program and how it has changed drastically with the growing list of drug manufacturers restricting access to medications provided by some contract pharmacies. In this webinar, we talked about what is happening, how to identify the impact on your particular 340B program, and how to develop a plan to move forward. Here’s a replay of 340B for Contract Pharmacies – The Good, Bad, and Downright Ugly.

On Tuesday, we hosted an informative webinar on the 340B program and how it has changed drastically with the growing list of drug manufacturers restricting access to medications provided by some contract pharmacies. In this webinar, we talked about what is happening, how to identify the impact on your particular 340B program, and how to develop a plan to move forward. Here’s a replay of 340B for Contract Pharmacies – The Good, Bad, and Downright Ugly.

The 340B program has changed drastically with the growing list of drug manufacturers restricting access to medications provided by some contract pharmacies. Now, more than ever, it is essential to understand what is happening, identify the impact on your particular 340B program, and develop a plan moving forward. That’s why we’re offering a webinar designed to tell you what you need to know. Register now for 340B for Contract Pharmacies – The Good, Bad, and Downright Ugly, at 2 p.m. ET on ...

To embed, copy and paste the code into your website or blog: On May 17, 2021, the Biden Administration took its first major action impacting the 340B Drug Discount Program.  In a forceful statement, the Administration made plain its views on a major controversy that has pitted drug manufacturers against 340B covered entities for the past year - proclaiming that drug manufacturers are violating the 340B statute by restricting covered entity access to 340B discounts for drugs dispensed through 3...

Tuesday, May 18, 2021 On May 17, 2021, the Biden Administration took its first major action impacting the 340B Drug Discount Program.  In a forceful statement, the Administration made plain its views on a major controversy that has pitted drug manufacturers against 340B covered entities for the past year - proclaiming that drug manufacturers are violating the 340B statute by restricting covered entity access to 340B discounts for drugs dispensed through 340B contract pharmacies.  Ba...

Chronicled Announces New MediLedger Working Group To Solve Medicaid Duplicate Discounts News provided by Share this article Share this article SAN FRANCISCO, April 27, 2021 /PRNewswire/ -- Chronicled, administrator of the MediLedger Network (the leading blockchain-powered industry network in Life Sciences), today announced the launch of a new working group dedicated to the development of a sustainable industry solution to the problem of Medicaid duplicate discounts against 340B priced drugs. A...

To embed, copy and paste the code into your website or blog: On December 30, 2020, the HHS Office of General Counsel (OGC) issued Advisory Opinion No. 20-06 finding the 340B Federal Drug Pricing Program requires drug manufacturers to extend 340B pricing to covered outpatient drugs dispensed through contract pharmacies. Recently, certain drug manufacturers have declined to distribute covered outpatient drugs through contract pharmacies at 340B pricing. The OGC concluded that this practice is imp...